Skip to content

Tarsus Pharmaceuticals, Inc. TARS Share-Based Payment Award Options Outstanding - Number

Share-Based Payment Award Options Outstanding - Number at other companies

Warby Parker logo
Warby ParkerWRBY
1.6M-2.0%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s share-based payment award options outstanding - number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s share-based payment award options outstanding - number?
Tarsus Pharmaceuticals, Inc. (TARS) reported share-based payment award options outstanding - number of 5.6M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s share-based payment award options outstanding - number changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s share-based payment award options outstanding - number increased by 5.2% year-over-year, from 5.4M to 5.6M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s share-based payment award options outstanding - number?
Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s share-based payment award options outstanding - number has grown at a 23.3% compound annual growth rate (CAGR), from 1.8M to 5.2M.
What does share-based payment award options outstanding - number mean?
This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.